Find information on thousands of medical conditions and prescription drugs.

Danazol

Danazol is a derivative of the synthetic steroid ethisterone, a modified testosterone. It was approved by the FDA as the first drug to treat specifically endometriosis, but its role as a treatment for endometriosis has been largely replaced by the GnRH agonists. more...

Home
Diseases
Medicines
A
B
C
D
Dacarbazine
Dactinomycin
Dalmane
Danazol
Dantrolene
Dapoxetine
Dapsone
Daptomycin
Daraprim
Darvocet
Darvon
Daunorubicin
Daunorubicin
Daypro
DDAVP
Deca-Durabolin
Deferoxamine
Delsym
Demeclocycline
Demeclocycline
Demerol
Demulen
Denatonium
Depakene
Depakote
Depo-Provera
Desferal
Desflurane
Desipramine
Desmopressin
Desogen
Desogestrel
Desonide
Desoxyn
Desyrel
Detrol
Dexacort
Dexamethasone
Dexamfetamine
Dexedrine
Dexpanthenol
Dextran
Dextromethorphan
Dextromoramide
Dextropropoxyphene
Dextrorphan
Diabeta
Diacerein
Diacetolol
Dial
Diamox
Diazepam
Diazoxide
Dibenzepin
Diclofenac
Diclohexal
Didanosine
Dieldrin
Diethylcarbamazine
Diethylstilbestrol
Diethyltoluamide
Differin
Diflucan
Diflunisal
Digitoxin
Digoxin
Dihydrocodeine
Dihydroergotamine
Dihydrotachysterol
Dilantin
Dilaudid
Diltahexal
Diltiazem
Dimenhydrinate
Dimercaprol
Dimetapp
Dimethyl sulfoxide
Dimethyltryptamine
Dimetridazole
Diminazene
Diovan
Dioxybenzone
Diphenhydramine
Diphenoxylate
Dipipanone
Dipivefrine
Diprivan
Diprolene
Diproteverine
Dipyridamole
Disulfiram
Disulfiram
Dizocilpine
Dobutamine
Docetaxel
Docusate sodium
Dofetilide
Dolasetron
Dolobid
Dolophine
Domperidone
Donepezil
Dopamine
Dopram
Doral
Doramectin
Doriden
Dornase alfa
Doryx
Dostinex
Doxapram
Doxazosin
Doxepin
Doxil
Doxil
Doxorubicin
Doxy
Doxycycline
Doxyhexal
Doxylamine
Drisdol
Drixoral
Dronabinol
Droperidol
Drospirenone
Duloxetine
Durabolin
Duragesic
Duraphyl
Duraquin
Dutasteride
Dv
Dyclonine
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z

The agent is fat-soluble, has a molecular weight of 337.5. Its CAS registry number is 17230-88-5.

Danazol decreases the pituitary hormones FSH and LH and exerts an antiproliferative effect upon the endometrium, leading to amenorrhea. This effect is useful for patients with endometriosis. Commonly, pelvic pain associated with endometriosis is improved as well.

Androgenic side effects are of concern as in sensitive female individuals, Danazol can enhance unwanted heir growth leading to hirsutism. On rare occasion, it may deepen the voice. Other side effects could be acne and oily skin. As Danazol is metabolized by the liver, it cannot be used by patients with liver disease, and long-term use needs to monitor liver function on a periodic basis. Some patients who use Danazol may experience weight gain and fluid retention.

Contrary to GNRH agonists Danazol does not induce osteoporosis. Also, symptoms of hot flashes tend to be less common or severe.

Danazol is contraindicated in pregnancy as it could masculinize a female fetus.

Danazol has been used for other indications, namely in the management of menorrhagia, of fibrocystic breast disease, and of hereditary angioedema.

In the USA, Danazol was initially marketed as Danocrine, before it became available as a generic drug.

Read more at Wikipedia.org


[List your site here Free!]


Hereditary angioedema presenting as acute pancreatitis
From CHEST, 10/1/05 by Evans R. Fernandez

INTRODUCTION: Hereditary angioedema (HAE) is an infrequent disorder characterized by abnormal serum levels and/or function of complement Clq esterase inhibitor (Clq INH). Clinically it presents with recurrent attacks of subcutaneous and/or submucosal swelling. When the gastrointestinal (GI) tract is involved, an exacerbation of HAE results in numeorus GI symptoms but rarely acute pancreatitis.

CASE PRESENTATION: A 40-year old man presented to our institution with a 1-month history of increasing anxiety and a 1-day history of intermittent abdominal pain, nausea, and vomiting. He described the pain as severe with radiation through to his back. He denied melena, hematochezia or previous gallbladder disease. He had a past medical history of peptic ulcer disease, generalized anxiety disorder and Clq esterase inhibitor deficiency, diagnosed at the age of two. His HAE attacks, occurring 5 to 6 times per year, generally lasted 1 to 2 days and were characterized by recurrent episodes of painless, nonpruritic swelling of the skin, abdominal pain and nausea. His medications included esomeprazole, sertraline, danazol and ondansetron, dyphenhydamine and hydromorphone as needed for angioedema flares. He was a nonsmoker and denied use of alcohol. On admission to the ICU, he was afebrile (98[degrees]F), hemodynamically stable with minimal sinus tachycardia and tachypnea. His exam was remarkable for epigastric tenderness but no hepatospleuomegaly or palpable abdominal masses. Laboratory studies revealed a white blood cell count of 19,300/cu mm, a hematocrit of 55 %, a serum amylase of 1,176 IU/L, a serum lipase of 11,485 IU/L, a serum aspartate and alanine aminotransferase of 68 IU/L and 105 IU/L respectively and a serum alkaline phosphatase of 138 IU/L. Other laboratory values, including serum total bilirubin, electrolytes, creatinine and triglycerides were normal. The Clq esterase inhibitor antigen was low at 7 mg/dl (normal, 19-37 mg/dl). With aggressive intravenous hydration, antibiotic prophylaxis, gastric decompression, pain control, and continuation of his home medications including esomeprazole and danazol, the patient improved and his pancreatic enzymes began to normalize within 72 hours. Abdominal ultrasonography revealed no biliary obstruction or gallbladder pathology. Contrast-enhanced computed tomography (CT) of the abdomen confirmed acute pancreatitis with patchy areas of pancreatic necrosis, mild bowel swelling and no intra or extrahepatic bile duct dilatation (Figure). Before discharge he underwent upper GI endoscopy, endoscopic retrograde cholangiopancreatography and analysis of bile for microlithiasis. These failed to explain the cause of pancreatitis thus favoring HAE as the most probable etiology.

[FIGURE OMITTED]

DISCUSSIONS: HAE affects between 1/10000-1/50000 people worldwide and can present after stressful triggering events, such as severe anxiety as seen in our patient. Besides subcutaneous swellings and occasionally fatal upper airway edema, it can also cause severe GI symptoms. However, a thorough literature search revealed only one case report describing HAE associated with pancreatitis. A high degree of clinical suspicion for possible pancreatitis should be maintained when facing a patient with history of HAE and abdominal pain. One quarter of HAE cases represent a new gene mutation so when no obvious cause for pancreatitis is found and recurrent episodes of pancreatitis occur then HAE should be considered in the differential diagnosis. Finally, treatment options are limited since in the United States Clq INH concentrate use has not been approved. Moreover, treatment with fresh frozen plasma (FFP) should be undertaken with caution since a number of cases have been reported with worsening of angioedema symptoms.

CONCLUSION: HAE, although rarely recognized and likely under-reported can cause pancreatitis via either swelling of the pancreas per se or by causing edema interfering with normal pancreatic drainage. Current treatment options for acute angioedema are limited with observation being the most common form of treatment since most attacks are self limited and of short duration.

DISCLOSURE: Evans Fernandez, None.

Evans R. Fernandez MD * Damir Matesic MD Nicholas E. Vlahakis MD Mayo Clinic, Rochester, MN

COPYRIGHT 2005 American College of Chest Physicians
COPYRIGHT 2005 Gale Group

Return to Danazol
Home Contact Resources Exchange Links ebay